



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab)	Lot.No.:	P99849C2
Target:	VEGFA, ANGPT2	Catalog:	CHBA067
Target Accession:	Q9UID3 & P15692	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	146.89 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

MASS




The detected molecular weight of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is 146.62 kDa.

Purity: SDS-PAGE




Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 96%.

Purity: SEC-HPLC



The purity of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is more than 95%, determined by SEC-HPLC.


Bioactivity: ELISA



Vanucizumab bound to ANG2 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Vanucizumab bound to in huANG2-His, and the EC50 was 0.288 nM.


The products are for research use only. Not for use in diagnostic procedures.

ELISA



Vanucizumab bound to VEGFA protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Vanucizumab bound to in huVEGFA-His, and the EC50 was 0.009 nM.

Function: Luciferase



Co-incubation of Vanucizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vanucizumab can neutralize VEGF-165, and the IC50 was 1.075 nM.

The products are for research use only. Not for use in diagnostic procedures.